We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




European Pathogenomics Network Adopts Common Research Agenda

By Biotechdaily staff writers
Posted on 04 Jun 2007
A European Union initiative has launched a research consortium that will concentrate on understanding the genome of pathogenic microorganisms (a new field called pathogenomics) and exploiting this knowledge to advance the cause of disease control.

The program to broaden the research effort on pathogenic microorganisms officially began in 2005 when the European Commission committed 6.7 millions euros (about US$9 million) over five years to form the European Network of Excellence EuroPathoGenomics (NoE EPG). More...
The network comprises 37 scientific laboratories from 13 different countries with headquarters at the University of Würzburg (Germany).

Since its establishment only two years ago, NoE EPG has completed a central virtual cell strain collection, which allows for the rapid searching of suitable data. Furthermore, the EuroPathoGenomics Graduate Academy (EGA) has been established, with more than 50 students participating in a number of training programs. The members of the network have now adopted a common research agenda, which lays out the core scientific challenges for the years to come and places emphasis on two aims in particular. In the future, researchers will focus more on the interaction between pathogens and hosts, rather than exclusively analyzing disease-causing microorganisms in isolation. In addition, microbiologists will call upon the expertise of bioinformatic experts to better manage the multitude of data that is produced in modern genomic research.

Another goal of the agenda is better cooperation between basic scientists and clinicians. "Our scientific language is not well understood by clinicians. We should learn more from each other,” said Dr. Werner Goebel, professor of molecular microbiology at the University of Würzburg (Germany).


Related Links:
European Network of Excellence EuroPathoGenomics
University of Würzburg

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.